Skip to main content

Table 2 Comparison of patient background characteristics between a TNFi insensitivity group and a poor response group. For each variable, p values of a simple comparison between the two groups using chi-squared test are shown

From: Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study

CategoryTNIi insensitivityRefractoryControlp value*
N%N%N%P1P2P3
GenderFemale7579.850182.973179.90.830.140.34
Male1920.210317.118420.1
Age group502324.512921.422824.90.620.410.48
51–602627.714924.720522.4
61–701920.216527.324626.9
712627.716126.723625.8
Disease duration (year)< 0.52223.47512.416518.00.45< 0.010.01
0.5–23133.016327.028431.0
2–51718.111719.415917.4
≥ 52425.524740.930633.4
DAS28-CRP at week 0< 3.233.261.0434.7< 0.01< 0.010.18
3.2–5.11212.89415.625928.3
> 5.17984.050283.161367.0
RF positivity**Negative2526.612721.024026.20.950.020.24
Positive6973.447378.367373.6
Use of GCNo6670.239365.170877.40.13< 0.010.30
Yes2829.821134.920722.6
Dose of MTX (mg/week)01313.88113.4839.10.22< 0.010.47
1–61010.67412.3798.6
7–92223.418931.321823.8
10–153234.017629.129432.1
> 151718.18413.924126.3
Failure in > 2 csDMARDsNo4446.830149.836539.90.16< 0.010.66
Yes5053.230350.255060.1
Entry phaseI2930.928747.532735.70.11< 0.01< 0.01
II2425.516928.017919.6
III2223.49515.728731.4
Drug typeIFX22.1111.8121.30.77< 0.01< 0.01
ETN1718.1427.011012.0
ADA55.3559.1556.0
GLM2223.423438.718620.3
CZP6771.331552.267473.7
  1. *P1, comparison between control and insensitivity; P2, comparison between control and refractory; P3, comparison between insensitivity and refractory
  2. **RF > 20 IU/mL was defined as positive
  3. p < 0.05
  4. DAS28 disease activity score for 28 joints, CRP c-reactive protein, MTX methotrexate, IFX infliximab, ETA etanercept, ADA adalimumab, GLM golimumab, CZP certolizumab, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs
\